SeouLin Bioscience서린바이오
038070 · KOSDAQ · ₩038070 · 서린바이오
₩3,625▲ ₩30 (0.83%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩77B | ₩75B | ₩90B | ₩102B | ₩81B |
| Cost of sales | ₩60B | ₩56B | ₩70B | ₩79B | ₩60B |
| Gross profit | ₩17B | ₩19B | ₩20B | ₩24B | ₩21B |
| Operating income | ₩692M | ₩953M | ₩2.5B | ₩8.6B | ₩7.3B |
| Net income | ₩574M | ₩3.1B | −₩2.3B | ₩10B | ₩16B |
| Net income to shareholders | ₩732M | ₩2.9B | −₩118M | ₩9.5B | ₩16B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩119B | ₩102B | ₩114B | ₩135B | ₩137B |
| Current assets | ₩72B | ₩60B | ₩73B | ₩87B | ₩101B |
| Cash and equivalents | ₩10B | ₩8.9B | ₩15B | ₩9B | ₩15B |
| Total liabilities | ₩33B | ₩15B | ₩29B | ₩47B | ₩60B |
| Current liabilities | ₩32B | ₩14B | ₩28B | ₩46B | ₩25B |
| Borrowings | ₩11B | ₩3.5B | ₩6.2B | ₩18B | ₩16B |
| Total equity | ₩86B | ₩87B | ₩85B | ₩88B | ₩77B |
| Shareholders' equity | ₩84B | ₩84B | ₩83B | ₩84B | ₩75B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩4.8B | −₩4.6B | ₩931M | −₩4.4B | ₩8.9B |
| Capital spending | — | — | — | ₩227M | ₩97M |
| Free cash flow | ₩4.8B | −₩4.6B | ₩931M | −₩4.6B | ₩8.8B |
| Dividends paid | ₩844M | ₩836M | ₩1.1B | ₩798M | ₩769M |
Consolidated where available. Amounts in won.
Also known as: SeouLin Bioscience / 서린바이오 / 038070 / KRX:038070
Source: KRX statistical information